EWA
ATYR

EverSource Wealth Advisors’s aTyr Pharma ATYR Stock Holding History

EverSource Wealth Advisors’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$685 Buy
1,149
+734
+177% +$479 ﹤0.01% 4071
2026
Q1 		$324 Buy
415
+254
+158% +$214 ﹤0.01% 4129
2025
Q4 		$126 Buy
+161
New +$132 ﹤0.01% 4080

Other funds holding ATYR

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EverSource Wealth Advisors's ATYR Position: Q2 2026 in Review

EverSource Wealth Advisors increased its aTyr Pharma (ATYR) stake by 177% in Q2 2026, buying an estimated $479 and bringing the position to 1,149 shares worth $685. The position accounts for ﹤0.01% of the portfolio, ranked #4071.

EverSource Wealth Advisors first reported a position in ATYR in Q4 2025 and has held it in 3 quarters since. 90 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.

  • EverSource Wealth Advisors held 1,149 shares of aTyr Pharma worth $685 as of Q2 2026.
  • EverSource Wealth Advisors bought 734 aTyr Pharma shares in Q2 2026, an estimated $479.
  • aTyr Pharma made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #4071 holding.
  • EverSource Wealth Advisors first reported a position in aTyr Pharma in Q4 2025 and has held it in 3 quarters since.
  • 90 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.